Why the study?
Do endothelin receptor antagonists improve outcomes in patients with pulmonary arterial hypertension?
Do endothelin receptor antagonists improve outcomes in patients with pulmonary arterial hypertension?
This review highlights the pathophysiological role of endothelin and the therapeutic potential of endothelin receptor antagonists like bosentan and sitaxsentan in managing pulmonary arterial hypertension.
Endothelin receptor antagonists merit rigorous randomized evaluation in pulmonary arterial hypertension; leaves open their adoption into clinical guidelines.
Endothelin (ET) has been identified as playing a fundamental role in many disease processes. Therapeutic efforts at interrupting ET's pathologic effects have focused on endothelin receptor antagonists (ERAs), of which two, bosentan and sitaxsentan, have been evaluated for the treatment of both primary and secondary pulmonary arterial hypertension (PAH). We discuss the multiple actions of ET, its role in various disease states, and the effects of ET receptor stimulation and blockade. Current classification and management of PAH are reviewed, along with the promise of greatly improved treatment generated by recent and ongoing clinical trials using ERAs.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: